A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The main disadvantage to transdermal delivery systems stems from the fact that the skin is a very effective barrier; as a result, only medications whose molecules are small enough to penetrate the skin can be delivered by this method. A wide variety of pharmaceuticals are now available in transdermal patch form.
Before these patches go into the market, they have to be carefully studied. One way to study these patches are through the use of Franz Diffusion Cell systems. This system is used to study the effects of temperature on the permeated amount of a specific drug on a certain type of membrane, which in this case would be the membrane that is used in the patches. A Franz Diffusion Cell system is composed of a receptor and a donor cell. In many of these research studies the following procedure is used. The donor cell is set at a specific temperature (the temperature of the environment ), while the receptor cell is set at different one (temperature of the body).
Different runs are performed using different temperatures to study the impact of temperature on the release of a certain medicament through a certain type of membrane. Although different concentrations of the medicament are used in this study, they do not affect the amount permeated through the membrane (the process is constant). From Chemical kinetics it’s concluded that these studies are zero order, since the concentration plays no role in the permeated amount through the membrane.
Some pharmaceuticals must be combined with substances, such as alcohol, within the patch to increase their ability to penetrate the skin in order to be used in a transdermal patch. Others can overwhelm the body if applied in only one place, and are often cut into sections and applied to different parts of the body to avoid this, such as nitroglycerin. Many molecules, however, such as insulin, are too large to pass through the skin without it being modified in some way. Several new technologies are being investigated to allow larger molecules to be delivered transdermally.
- The highest selling transdermal patch in the United States is the nicotine patch, which releases nicotine in controlled doses to help with cessation of tobacco smoking. The first commercially available vapour patch to reduce smoking was approved in Europe in 2007.
- Two opioid medications used to provide round-the-clock relief for severe pain are often prescribed in patch form: Fentanyl CII (marketed as Duragesic) and Buprenorphine CIII (marketed as BuTrans).
- Hormonal patches
- Nitroglycerin patches are sometimes prescribed for the treatment of angina in lieu of sublingual pills.
- The anti-hypertensive drug Clonidine is available in transdermal patch form under the brand name Catapres-TTS.
- Emsam, a transdermal form of the MAOI selegiline, became the first transdermal delivery agent for an antidepressant approved for use in the U.S. in March 2006.
- Daytrana CII, the first transdermal delivery agent for the Attention Deficit Hyperactivity Disorder (ADHD) drug methylphenidate (otherwise known as Ritalin or Concerta), was approved by the FDA in April 2006. It's key formulator, Juan Mantelle, is one of the leading transdermal developers in the nation. He is currently serving as CEO for ProSolus Pharmaceuticals.
- Vitamin B12 may also be administered through a transdermal patch. Cyanocobalamin, a highly stable form of vitamin B12, is compatible with transdermal patching.
- Rivastigmine, an Alzheimer's treatment medication, was released in patch form in 2007, under the brand name Exelon
- In 2005, the FDA announced that they were investigating reports of death and other serious adverse events related to narcotic overdose in patients using Duragesic, the fentanyl transdermal patch for pain control. The Duragesic product label was subsequently updated to add safety information in June 2005.
- In 2007, Shire and Noven Pharmaceuticals, manufacturers of the Daytrana ADHD patch, announced a voluntary recall of several lots of the patch due to problems with separating the patch from its protective release liner. Since then, no further problems with either the patch or its protective packaging have been reported.
- In 2008, two manufacturers of the Fentanyl patch, ALZA Pharmaceuticals (a division of major medical manufacturer Johnson & Johnson) and Sandoz, subsequently issued a recall of their versions of the patch due to a manufacturing defect that allowed the gel containing the medication to leak out of its pouch too quickly, which could result in overdose and death. As of March 2009, Sandoz—now manufactured by ALZA—no longer uses gel in its transdermal fentanyl patch; instead, Sandoz-branded fentanyl patches use a matrix/adhesive suspension (where the medication is blended with the adhesive instead of held in a separate pouch with a porous membrane), similar to other fentanyl patch manufacturers such as Mylan and Janssen.
- In 2009, the FDA announced a public health advisory warning of the risk of burns during MRI scans from transdermal drug patches with metallic backings. Patients should be advised to remove any medicated patch prior to an MRI scan and replace it with a new patch after the scan is complete.
- In 2009, an article in Europace journal detailed stories of skin burns that occurred with transdermal patches that contain metal (usually as a backing material) caused by shock therapy from external as well as internal cardioverter defibrillators (ICD).
The main components to a transdermal patch are:
- Liner - Protects the patch during storage. The liner is removed prior to use.
- Drug - Drug solution in direct contact with release liner
- Adhesive - Serves to adhere the components of the patch together along with adhering the patch to the skin
- Membrane - Controls the release of the drug from the reservoir and multi-layer patches
- Backing - Protects the patch from the outer environment
There are five main types of transdermal patches.
The adhesive layer of this system also contains the drug. In this type of patch the adhesive layer not only serves to adhere the various layers together, along with the entire system to the skin, but is also responsible for the releasing of the drug. The adhesive layer is surrounded by a temporary liner and a backing.
The multi-layer drug-in adhesive patch is similar to the single-layer system in that both adhesive layers are also responsible for the releasing of the drug.One of the layers is for immediate release of the drug and other layer is for control release of drug from the reservoir. The multi-layer system is different however that it adds another layer of drug-in-adhesive, usually separated by a membrane (but not in all cases). This patch also has a temporary liner-layer and a permanent backing. The drug release from this depends on memebrane permeability and diffusion of drug molecules.
Unlike the Single-layer and Multi-layer Drug-in-adhesive systems the reservoir trans dermal system has a separate drug layer. The drug layer is a liquid compartment containing a drug solution or suspension separated by the adhesive layer. This patch is also backed by the backing layer. In this type of system the rate of release is zero order. Here drug reservoir is totally encapsulated in a shallow compartment molded from a drug impermeable metallic plastic laminates, the another side of this so-called rate controlling membrane madeup of polymeric membrane like Ethyl Vinyl Acetate.
The Matrix system has a drug layer of a semisolid matrix containing a drug solution or suspension. The adhesive layer in this patch surrounds the drug layer partially overlaying it. Also known as a monolithic device.
In this type of patch the adhesive layer not only serves to adhere the various layers together but also to release vapour. The vapour patches are new on the market and they release essential oils for up to 6 hours. The vapour patches release essential oils and are used in cases of decongestion mainly. Other vapour patches on the market are controller vapour patches that improve the quality of sleep. Vapour patches that reduce the quantity of cigarettes that one smokes in a month are also available on the market.
A transdermal patch is classified by the U.S. Food and Drug Administration as a combination product, consisting of a medical device combined with a drug or biological product that the device is designed to deliver. Prior to sale in the United States, any transdermal patch product must apply for and receive approval from the Food and Drug Administration, demonstrating safety and efficacy for its intended use.
- Segal, Marian. "Patches, Pumps and Timed Release: New Ways to Deliver Drugs". Food and Drug Administration. Archived from the original on 2007-02-10. Retrieved 2007-02-24.
- "FDA approves scopolamine patch to prevent peri-operative nausea". Food and Drug Administration. 1997-11-10. Archived from the original on 2006-12-19. Retrieved 2007-02-12.
- Prausnitz M, Langer R. Transdermal drug delivery. Nature Biotechnology. Volume 26, Number 11, Pages 1261-1268, November 2008
- Nachum Z, Shupak A, Gordon CR (2006). "Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications". Clinical Pharmacokinetics 45 (6): 543–66. PMID 16719539.
- Berner B, John VA (February 1994). "Pharmacokinetic characterisation of transdermal delivery systems". Clinical pharmacokinetics 26 (2): 121–34. doi:10.2165/00003088-199426020-00005. PMID 8162656.
- First Databank Inc. "Clonidine - Transdermal (Catapres-TTS) side effects, medical uses, and drug interactions". Retrieved 2010-09-28.
- Peck, Peggy (2006-03-01). "FDA Approves First Antidepressant Transdermal Patch". Retrieved 2010-09-28.
- Cabray, Matthew (2006-04-12). "Transdermal Patch Approved For Treatment Of ADHD". Retrieved 2010-09-28.
- PatchBrothers, lifestyle, party patches, body boosts and transdermal pick me ups
- "FDA ALERT (07/2005): Narcotic Overdose and Death". Food and Drug Administration. 2005-07-15. Archived from the original on 2007-02-20. Retrieved 2007-02-24.
- Megget, Katrina (2007-09-05). "ADHD Transdermal Patches Withdrawn". Retrieved 2010-09-28.
- Silverman, Ed (2008-02-12). "J&J and Sandoz Recall Fentanyl Patches". Retrieved 2010-09-28.
- As stated on the packaging and labels of Sandoz-branded Fentanyl Transdermal System products, revised March 2009.
- "FDA Public Health Advisory: Risk of Burns during MRI Scans from Transdermal Drug Patches with Metallic Backings". Retrieved March 9, 2009.[dead link]
- Brown, MR: "Analgesic patches and defibrillators: a cautionary tale", Europace,2009 Nov;11(11):1552-3
- "Combination Products; FAQ". Retrieved April 10, 2012.
- "Transderm Scōp" (PDF). Food and Drug Administration. 1998. Archived from the original on 2007-08-10. Retrieved 2007-02-12.
|Wikimedia Commons has media related to Transdermal patches.|